Tessara Therapeutics

Executive Summary

Tessara Therapeutics is an Australian preclinical biotechnology company pioneering the RealBrain® platform, a proprietary synthetic hydrogel system that generates scalable, reproducible 3D human neural micro-tissues from iPSC-derived neural stem cells. The platform produces ArtiBrain™ (healthy) and ADBrain™ (Alzheimer’s disease) models, offering human-relevant, high-throughput tools for CNS drug discovery and neuro-regeneration research. Founded in 2020, the company addresses a critical bottleneck in neurology drug development—the lack of physiologically relevant in vitro models—by providing reproducible human neural tissues that can accelerate target validation and compound screening. Tessara's technology has the potential to reduce reliance on animal models and improve translational success rates in Alzheimer's disease and other CNS disorders. Currently at the preclinical stage, the company is actively seeking partnerships and funding to validate its platform with pharmaceutical partners and advance toward commercial adoption.

Upcoming Catalysts (preview)

• H2 2026Series A funding announcement40% success
• H1 2027Research collaboration with a top-20 pharma company30% success
• Q4 2026Publication of validation data for ADBrain™ in a peer-reviewed journal60% success